TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00992641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental diet
Description: Diet based on Nordic recommendations: rich in whole grain products, berries, fruits and vegetables, recommended fat quality. Realised based on eating habits of each Nordic country.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control diet
Description: Diet based on the information of the current dietary intake and food consumption in Nordic countries.
Study: NCT02214342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: Experimental: Balance Training Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes.
Study: NCT02362893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct Observed Therapy
Description: Patients allocated to the intervention group take their medication (from original blister packaged) in front of the invistigator who observe the patient swallowing the medication. To secure the principals of Direct Observed Therapy, the patient do not leave the clinic for two hours.
Study: NCT04293523

Intervention type: DRUG
Intervention: ELOCTA
Description: Extended half-life factor VIII product
Study: NCT04807881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keynatinib
Description: All subjects shall be treated with Keynatinib twice a day (once every 12 hours), 20 mg each time, fasting within 2 hours before and 1 hour after taking the drug, and taking warm water when taking the drug. It is recommended to take the drug at the same time every day. In case of missed administration, the subjects should be instructed to take it as soon as possible when they think of it on the same day. If it is within 3 hours later than the scheduled administration, the study drug should be taken as soon as possible; if the interval is \> 3 hours, skip this time and take the next dose at the normal scheduled time. Do not take double dose at one time. Every 28 days is a treatment cycle until the specified interview completed, PD, intolerable toxicity, death occurs or withdraw from the study (including withdrawal of informed consent by the subject or termination of the study when the investigator judges that the risk is greater than the benefit), whichever occurs first.
Study: NCT03393039

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative Affect Task
Description: fMRI stress task
Study: NCT00792909

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal conjugate vaccine GSK1024850A
Description: Intramuscular injection, 2 doses
Study: NCT03503110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrocorticography with electrostimulation
Description: The investigators aim to establish a relationship between dMRI SC measures, direct measures of electrical properties of the human brain cortex obtained with electrocorticography (ECoG), and response elicited by direct electrostimulation of the brain (DES)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dRMI
Description: The investigators aim to establish a relationship between dMRI SC measures, direct measures of electrical properties of the human brain cortex obtained with electrocorticography (ECoG), and response elicited by direct electrostimulation of the brain (DES)
Study: NCT00385918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat Training
Description: The Lokomat is a robotically assisted partial weight suspension treadmill training device that has the potential to restore leg function in persons with incomplete leg paralysis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home stretching then Lokomat training
Description: Patients will be instructed by a physical therapist on how to perform a home stretching protocol 3 times per week for 3 months. The stretching will be monitored via telephone by the study coordinator. This will be an active control arm. After 3 months the patients will be crossed over to Lokomat training for an additional 3 months. This training will be the same as given to the individuals originally randomized to the Lokomat treatment intervention.
Study: NCT01899820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether lumefantrine
Description: Artemether 20mg Lumefantrine 120mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin piperaquine
Description: Dihydroartemisinin 20mg Piperaquine 160mg
Study: NCT02580253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individualized Chemotherapy
Description: Two drug combination adjuvant chemotherapy based on the Adenosine Triphosphate Tumor Chemosensitivity(Oxaliplatin, Gemcitabine, Irinotecan, Paclitaxel,docetaxel, Fluorouracil,Doxorubicin,Cisplatin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: Oxaliplatin,Fluorouracil
Study: NCT01386931

Intervention type: PROCEDURE
Intervention: EUS-guided FNA performed with on-site Cytopathologist
Description: Patients assigned to the on-site cytopathologist arm will have the cytopathologist dictate the number of FNA passes performed by the endosonographer. This number will be based on the adequacy of specimen and the ability to provide a preliminary diagnosis.

Intervention type: PROCEDURE
Intervention: EUS-guided FNA performed without on-site Cytopathologist
Description: In the absence of an on-site cytopathologist, the endosonographer will perform a predetermined number of 7 passes (standard of care in the absence of an on-site cytopathologist).
Study: NCT02211378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observer
Description: Trainees are in the role of observers (not actively participating in simulation scenario) during first 2 simulation sessions, then placed in the role in the 'hotseat' actively participating during the third simulation session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hotseat
Description: Trainees in the hotseat group are placed in the 'hotseat' to actively participate and manage the simulated medical crises in the simulation scenarios.
Study: NCT02227784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT00873717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dentary
Description: cleaning-up of oral cavity, with trimestrial dental and oral check-up with counseling for appropriate care (if needed).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: control of the administration of dietary prescriptions, incitement to eat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dentary + Nutrition
Description: trimestrial follow-up of patients and counseling for appropriate care (if needed), in order to restore a minimum masticatory function, associated with particular focus on the realization of daily oral wash.~associated with control of the administration of dietary prescriptions, incitement to eat.
Study: NCT00643019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAFE Behavioral Intervention
Description: Group cognitive behavioral intervention sessions

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Individual Sexually Transmitted Infection Risk Reduction Counseling
Study: NCT03940196

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-100L(O)
Description: Patients receive continuous TTFields treatment using the NovoTTF-100L(O) device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the abdomen/pelvis. The treatment enables the patient to maintain regular daily routine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m\^2 intravenous infusion will be administered weekly for 8 weeks and then on Days 1, 8 and 15 of each subsequent 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m\^2 intravenous infusion will be administered weekly for 8 weeks and then on Days 1, 8 and 15 of each subsequent 28-day cycle.
Study: NCT03153046

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: prebiotics
Description: Bimuno (BGOS): The active supplement of the food supplement (Bimuno) used in this study is called galacto-oliogosaccharides (Bimuno®, BGOS). BGOS is a compound metabolised by specific bifidobacteria, which are beneficial bacteria, in our colon. Bimuno (2.3 calories) is composed by the following ingredients per gram of Bimuno: 0.96g dry matter; \<01g Fat; \<0.06g Protein; 0.821g GOS; 0.119g Lactose; 0.0331g Glucose and 0.0029g Galactose. Bimuno is tasteless. Bimuno will be supplied in coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin is a polysaccharide in powder form, which grows most bacteria in the gut, and not specifically the beneficial bifidobacteria. The placebo will also be provided in daily coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink. This placebo has been used in previous studies, in which Bimuno was used as the active intervention. The placebo will be similar in taste and colour to the active intervention.
Study: NCT00196105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 6 mm Nitinol Zilver Stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10 mm Nitinol Zilver Stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 10 mm Stainless Steel Wallstent
Study: NCT02587767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 577-MPL
Description: All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm LaserSystem) in 577-MPL arm. The individual power for the patient was titrated at a normal area of near the affected area in micropulse model.The power titration was started at 700 milliwatt(mW) and then gradually increased until a just visible burn was seen. When this threshold was reached, the power was reduced by 50%, using a 100-μm spot diameter and a 200-ms duration with 5 % duty cycle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HD-PDT
Description: 5 minutes after the start of the half-dose verteporfin infusion, the PDT treatment will been performed in HD-PDT arm. The treatment is performed with standard fluency (50 J/cm2), a PDT laser wavelength of 689 nm, and a standard treatment duration of 83 seconds.
Study: NCT01005576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan
Description: Days -50 to -21: Hydroxyurea 30mg/kg po Day -22: Alemtuzumab 3mg IV Day -21: Alemtuzumab 10mg IV Day -20: Alemtuzumab 15mg IV Day -19: Alemtuzumab 20mg IV Day -8: Fludarabine 30mg/m2 IV Day -7: Fludarabine 30mg/m2 IV Day -6: Fludarabine 30mg/m2 IV Day -5: Fludarabine 30mg/m2 IV Day -4: Fludarabine 30mg/m2 IV Day -4: Thiotepa 8mg/kg IV Day -3: Melphalan 140mg/m2 IV Day 0: Stem cell infusion
Study: NCT01893697

Intervention type: OTHER
Intervention: HRCT scan in a specific postural position
Description: HRCT Scan taken in supine and lateral position
Study: NCT00784719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Ophthalmic topical solution, low dose, dosed at least once/day, 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Ophthalmic topical solution, medium dose, dosed at least once/day, 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Ophthalmic topical solution, intermediate dose, dosed at least once/day, 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Ophthalmic topical solution, high dose, dosed at least once/day, 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Ophthalmic topical solution, 0.05%, dosed at least once/day, 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CP-690,550 Vehicle
Description: Ophthalmic topical solution, dosed at least once/day, 8 weeks
Study: NCT04157088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide (Nubeqa, BAY1841788)
Description: 600mg, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160mg, once daily
Study: NCT03509181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-Change
Description: smartphone delivered word-sentence association task that encourages a healthier interpretive style

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Tracking
Description: smartphone delivered self-monitoring of anxiety and depression symptoms

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptom Tracking
Description: smartphone delivered self-monitoring of anxiety and depression symptoms
Study: NCT05701254

Intervention type: PROCEDURE
Intervention: Transilial bone biopsy
Description: The transiliac bone biopsy will be performed on each subject under local anesthesia, and conscious sedation. From one skin incision located \~2cm posterior and inferior to the anterior-superior pelvic spine on one side of the pelvis, the investigators will obtain two iliac bone specimens, each 7.5 mm in diameter, cylindrical in shape, and including both inner and outer cortices and the intervening trabecular bone.

Intervention type: PROCEDURE
Intervention: Transilial bone biopsy
Description: The transiliac bone biopsy will be performed on each subject under local anesthesia, and conscious sedation. From one skin incision located \~2cm posterior and inferior to the anterior-superior pelvic spine on one side of the pelvis, the investigators will obtain two iliac bone specimens, each 7.5 mm in diameter, cylindrical in shape, and including both inner and outer cortices and the intervening trabecular bone.
Study: NCT02288819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Weight monitoring
Description: The body weight of patients is measured each morning in identical conditions on the same balance during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loop diuretic downtitration
Description: The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.~In case of a total daily maintenance dose ≤40 mg furosemide OR ≤1 mg bumetanide OR ≤20 mg torsemide, the loop diuretic is completely stopped.~In case of a total daily maintenance dose \>40 mg furosemide OR \>1 mg bumetanide OR \>20 mg torsemide, the loop diuretic dose is halved.
Study: NCT03962621

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Fotona 4D 1064 nm laser
Description: The 1064 nm laser can penetrate deep into the skin to explode pigment particles, destroy blood vessels and heat the dermal collagen by targeting melanin and haemoglobin.(1) Frac3®: 30-35 J/cm2, 1.6 ms pulse width, 4mm spot size, unilaterally accumulated 2000 shots; and (2) PIANO®: 160 J/cm2, 5s pulse width, spot size 9mm, unilaterally accumulated 20000 shots, to increase and maintain facial skin temperature to 39-40oC.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fotona 4D 1064 nm laser
Description: The 1064 nm laser can penetrate deep into the skin to explode pigment particles, destroy blood vessels and heat the dermal collagen by targeting melanin and haemoglobin.(1) Frac3®: 30-35 J/cm2, 1.6 ms pulse width, 4mm spot size, unilaterally accumulated 2000 shots; and (2) PIANO®: 160 J/cm2, 5s pulse width, spot size 9mm, unilaterally accumulated 20000 shots, to increase and maintain facial skin temperature to 39-40oC.
Study: NCT04737720

Intervention type: DRUG
Intervention: Recombinant LCAT
Description: iv infusion
Study: NCT03962621

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Fotona 4D 2940 nm laser
Description: Er:YAG 2940nm have been considered as a good treatment of facial aging, especially in wrinkles.(1) Smooth®: 9-10 J/cm2, 7mm spot size, which is sequentially delivered to upper and lower labial mucosa and buccal mucosa to unilaterally accumulate 5000 shots; (2) SupErficial™: 0.5-1.0 J/cm2, 7mm spot size, a single pass

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fotona 4D 2940 nm laser
Description: Er:YAG 2940nm have been considered as a good treatment of facial aging, especially in wrinkles.(1) Smooth®: 9-10 J/cm2, 7mm spot size, which is sequentially delivered to upper and lower labial mucosa and buccal mucosa to unilaterally accumulate 5000 shots; (2) SupErficial™: 0.5-1.0 J/cm2, 7mm spot size, a single pass
Study: NCT02902042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Dose determined in phase I. Start dose: 450 mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Dose determined in phase I. Start dose: 45 mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Dose determined in phase I. Start dose: 200 mg q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab alone
Description: 200 mg q3w
Study: NCT03666247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealthMindr Application
Description: From baseline to 3-month post-test, participants in the intervention arm are granted access and instructed to interact regularly with the HealthMindr messaging platform. The HealthMindr messaging platform delivers messages relevant to both general audiences of sexually-active MSM, as well as messages relevant only to specific subgroups of HIV-positive men, and currently higher and lower risk HIV-negative men. Answers provided during the assessments determine which subset of messages are delivered to app users, with information such as HIV status, changes in self-reported risk behaviors, or other factors that influence the relevance of any given message. The HealthMindr application also offers free condoms, lube, and a HIV and STI testing kits.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist
Description: Participants assigned to the waitlist-control arm will be given a welcome sheet orienting them to the study. The message they view will include the same resources links provided to the intervention arm. The information will cover the importance of testing, links to an online mapping tool about the HIV epidemic in the United States (AIDSVu) and resources to locate HIV testing services and prevention information in their area. No information recommending frequency of testing will be given in the welcome greeting.
Study: NCT00596050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine and midazolam
Description: ketamine 1 mg/kg/dose, midazolam 0.05 mg/kg/dose max 2 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etomidate, fentanyl, and lidocaine
Description: etomidate 0.2 mg/kg/dose, fentanyl 1 microgram/kg/dose, lidocaine 0.5 mg/kg/dose
Study: NCT04663243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thinking healthy Program sessions designed for antenatal period
Description: Low line psychosocial intervention based on the principles of Cognitive Behavior Therapy (CBT), designed for non-specialist will be applied for expectant women experiencing depression during mid to late-pregnancy. It uses the core principles and strategies of the Thinking Healthy Program (THP). Four core sessions and two booster sessions will be applied, designed for antenatal period to prevent antenatal and post partum depression.
Study: NCT03893955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-927
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-927
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-927
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-927
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-927
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-927
Description: Intravenous (IV) Infusion
Study: NCT04066881

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48)
Description: 1. DNA-HIV-PT123 HIV vaccine includes three DNA plasmids that encode clade C ZM96 Gag, clade C ZM96 Env, and CN54 Pol-Nef.~2. AIDSVAX® B/E is a bivalent HIV gp120 glycoprotein encompassing both subtype B (MN) and subtype E (A244) proteins that are adsorbed onto 600mcg of aluminum hydroxide gel suspension as adjuvant.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48)
Description: 1. DNA-HIV-PT123 HIV vaccine includes three DNA plasmids that encode clade C ZM96 Gag, clade C ZM96 Env, and CN54 Pol-Nef.~2. AIDSVAX® B/E is a bivalent HIV gp120 glycoprotein encompassing both subtype B (MN) and subtype E (A244) proteins that are adsorbed onto 600mcg of aluminum hydroxide gel suspension as adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48)
Description: 1. DNA-HIV-PT123 (see above)~2. CN54gp140+MPLA-L. Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity.~3. MVA-CMDR (Modified Vaccinia Ankara-Chiang Mai Double Recombinant) is a non-replicating, highly attenuated strain of Vaccina virus that has been genetically engineered to express the HIV-1 genes envgp160 CM235 Subtype E and gag and pol CM240 Subtype A (integrase-deleted and reverse transcriptase non-functional).